SCHEMBL1945482

SCHEMBL1945482

CCCCn1c(N)c(N)c(=O)[nH]c1=O

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.71
ATM Q13315 2/20 0.71
KDM4E B2RXH2 8/20 0.65
GAA P10253 6/20 0.65
ALDH1A1 P00352 6/20 0.65
LMNA P02545 1/20 0.63
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
GLA P06280 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PKM P14618 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
PDE4A P27815 1/20 0.51
ADORA2A P29274 1/20 0.51
PDE4B Q07343 1/20 0.51
PDE4C Q08493 1/20 0.51
PDE4D Q08499 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713217 0.95 MAPT (0.64) MAPTATMKDM4EGAAALDH1A1
SCHEMBL1565331 0.89 MAPT (0.69) MAPTATMKDM4EGAAALDH1A1
Hydrochloric Acid SCHEMBL4692433 0.87 MAPT (0.67) MAPTATMKDM4EGAAALDH1A1
SCHEMBL1947188 0.82 MAPT (0.49) MAPTATMKDM4EGAAALDH1A1
SCHEMBL8579776 0.81 MAPT (0.49) MAPTATMKDM4EGAAALDH1A1
SCHEMBL1546553 0.81 MAPT (0.67) MAPTATMKDM4EGAAALDH1A1
SCHEMBL1943360 0.81 MAPT (0.47) MAPTATMKDM4EGAAALDH1A1
SCHEMBL1947204 0.80 MAPT (0.63) MAPTATMKDM4EGAAALDH1A1
SCHEMBL562514 0.78 MAPK10 (0.51) MAPTATMKDM4EGAAALDH1A1
SCHEMBL1947280 0.78 MAPT (0.48) MAPTATMKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111072574-B 5, 6-diamino-1, 3-dialkyl substituted uracil and its preparation method 广东工业大学 2023-03-14 CN disclosed
US-11225481-B2 Xanthine derivative inhibitors of BET proteins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-01-18 US disclosed
US-11225481-B2 Xanthine derivative inhibitors of BET proteins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-01-18 US disclosed
EP-3397640-B1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INST NAT SANTE RECH MED (FR) 2021-08-04 EP disclosed
EP-3397640-B1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INST NAT SANTE RECH MED (FR) 2021-08-04 EP disclosed
CN-111072574-A 5, 6-diamino-1, 3-dialkyl substituted uracil and its preparation method 广东工业大学 2020-04-28 CN disclosed
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-09-26 US disclosed
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-09-26 US disclosed
EP-3397640-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2018-11-07 EP disclosed
WO-2017114843-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-07-06 WO disclosed
US-20030139428-A1 A2B adenosine receptor antagonists GILEAD SCIENCES, INC. 2003-07-24 US disclosed
US-20030060627-A1 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives ALMIRALL PRODESFARMA, S.A. (ES) 2003-03-27 US disclosed
EP-1198464-A1 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES Almirall Prodesfarma, S.A. (ES) 2002-04-24 EP disclosed
WO-2001007441-A1 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES ALMIRALL PRODESFARMA S.A. (ES) 2001-02-01 WO disclosed
US-4644001-A BRONCHODILATOR, CARDIOTONIC AGENTS AKTIEBOLAGET DRACO (SE) 1987-02-17 US disclosed
US-4581451-A ALKYLATION AND CYCLIZATION OF A URACIL COMPOUND NESTEC S.A. (CH) 1986-04-08 US disclosed
US-4548818-A Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines AKTEBOLAGET DRACO, A COMPANY OF SWEDEN (SE) 1985-10-22 US disclosed
EP-0039780-B1 DI- OR TRISUBSTITUTED XANTHINES WITH NEUROLEPTIC ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM SOCIETE DES PRODUITS NESTLE S.A. (CH) 1985-04-10 EP disclosed
US-4469698-A SEDATIVES, TRANQUILIZERS SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) 1984-09-04 US disclosed
EP-0039780-A1 Di- or trisubstituted xanthines with neuroleptic activity, process for their preparation and pharmaceutical preparations containing them SOCIETE DES PRODUITS NESTLE S.A. (CH) 1981-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060627-A1 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives HYOU1, CHN2, PURB MAPT 4809/4885ATM 4633/4885KDM4E 4355/4885
US-20190292186-A1 XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS BET1, BRD4, BRD3 MAPT 2558/4885ATM 2292/4885KDM4E 276/4885
US-20030139428-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA1 MAPT 4828/4885ATM 2334/4885KDM4E 4096/4885
US-11225481-B2 Xanthine derivative inhibitors of BET proteins BET1, BRD4, BRD3 MAPT 2558/4885ATM 2292/4885KDM4E 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.